Treatment of Refractory Systemic Hodgkin Lymphoma and Secondary CNS Involvement with Brentuximab Vedoti

Abstract

The occurrence of CNS involvement in Hodgkin lymphoma is rare and prognosis is poor. This case report describes treatment of 32year-old woman with systemic Hodgkin lymphoma refractory to several lines of chemotherapy and radiotherapy.

CNS involvement was documented during the progression. Systemic and CNS involvements of Hodgkin lymphoma were treated by two cycles of brentuximab vedotin and bendamustine alternating with two cycles of high dose methotrexate in combination with procarbazine and dexamethasone.

Above mentioned treatment led to a partial remission. Subsequently the patient underwent a high dose chemotherapy and autologous stem cell transplantation and consolidation treatment with 16 cycles of brentuximab vedotin.

The patient progressed and died six months after the last dose of brentuximab vedotin.